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A B S T R A C T
Drug delivery to the central nervous system remains a major problem due to biological barriers. The blood-brain-
barrier can be bypassed by administering drugs intrathecally directly to the cerebrospinal fluid (CSF). The
glymphatic system, a network of perivascular spaces promoting fluid exchange between CSF and interstitial
space, could be utilized to enhance convective drug delivery from the CSF to the parenchyma. Glymphatic flow is
highest during sleep and anesthesia regimens that induce a slow-wave sleep-like state. Here, using mass spec-
trometry and fluorescent imaging techniques, we show that the clinically used α2-adrenergic agonist dexme-
detomidine that enhances EEG slow-wave activity, increases brain and spinal cord drug exposure of intrathecally
administered drugs in mice and rats. Using oxycodone, naloxone, and an IgG-sized antibody as relevant model
drugs we demonstrate that modulation of glymphatic flow has a distinct impact on the distribution of in-
trathecally administered therapeutics. These findings can be exploited in the clinic to improve the efficacy and
safety of intrathecally administered therapeutics.
1. Introduction
Drug delivery to the central nervous system (CNS) is particularly
difficult due to the blood-brain barrier (BBB). Direct administration to
the cerebrospinal fluid (CSF) is used to bypass the BBB to deliver several
classes of small-molecule drugs, including local anesthetics, analgesics,
antibiotics, and chemotherapy agents, as well as larger therapeutics
such as polypeptides [1], proteins [2], or oligonucleotides. For ex-
ample, the intrathecally administered oligonucleotide nusinersen is
currently the only disease-modifying treatment for spinal muscular
atrophy [3]. However, the slow diffusion rate of solutes from the CSF to
the CNS interstitial fluid (ISF) has been thought to severely restrict the
entry of intrathecally administered therapeutics to the deeper regions of
the brain and spinal cord [4].
The recently discovered glymphatic pathway is a fluid transport
system that facilitates the influx of CSF to the CNS interstitium. [5,6]
CSF in the subarachnoid space flows along the periarterial spaces of
large leptomeningeal arteries [6,7]. After branch points of the arterial
vasculature, CSF flows to deeper brain and spinal cord structures
alongside the periarterial (Virchow-Robin) spaces of penetrating ar-
teries [6,8]. Astrocytic endfeet that face the periarterial spaces express
highly polarized aquaporin 4 (AQP4) water channels that facilitate CSF
influx from the periarterial spaces into the interstitial space [9]. This
CSF-ISF exchange process facilitates a net fluid movement in the brain
interstitium towards venous perivascular sites, which in turn drain to
arachnoid granulations, cranial and spinal nerves, as well as meningeal
lymphatic vessels [10,11]. Glymphatic fluxes effectively clear the brain
of many endogenous macromolecules, such as amyloid-β [6] and tau
[12] and small-molecular weight metabolites, such as lactate [13]. In
addition to clearance, glymphatic flow has also been shown to dis-
tribute fluorescent tracers of different sizes from the CSF into the brain
[6,7] and the spinal cord [14].
The glymphatic pathway is predominantly active during sleep [15]
or anesthesia that promotes slow-wave oscillations [15,16]. Decreased
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CNS noradrenergic tone, an important feature of deep NREM sleep, has
been associated with high glymphatic influx as it decreases resistance to
interstitial fluid flow by enlarging the interstitial space volume [15].
Dexmedetomidine, a selective α2-adrenergic agonist, is a sedative agent
commonly used in intensive care and procedural sedation [17,18]. It
induces a sedative state similar to stage II–III NREM sleep with respect
to the increased slow-wave delta oscillations in the electro-
encephalogram (EEG) and dramatically decreased noradrenergic tone
[19]. So far, it remains largely uncharacterized whether pharmacologic
modulation of glymphatic flow by dexmedetomidine or other drugs
could affect the CNS pharmacokinetics of drugs administered either
intrathecally or systemically.
In clinical practice, intrathecal drugs are usually administered
during the awake state when the glymphatic system is disengaged. We
hypothesized that enhancing glymphatic CSF influx by either systemic
or intrathecal dexmedetomidine should increase the delivery of in-
trathecally administered drugs from the CSF to the interstitium. We
studied the glymphatic CNS delivery of clinically relevant small-mole-
cule drugs as well as an IgG-sized therapeutic. We found that in several
brain areas critical for opioid analgesia and toxicity the availability of
intrathecally administered oxycodone and naloxone were markedly
increased by subcutaneous or intrathecal dexmedetomidine co-admin-
istration. We propose that the modulation of the glymphatic system by
α2-adrenergic agonists could be potentially used clinically to enhance
the CNS delivery of certain intrathecally administered drugs.
2. Materials and methods
2.1. Animals
All procedures were approved by the local authorities (Regional
State Administrative Agency of Southern Finland, ESAVI/9697/
04.10.07/2017, Animal Experiments Council under the Danish Ministry
of Environment and Food, 2015-15-0201-00535, and University
Committee on Animal Resources of the University of Rochester Medical
Center, 2011-023). Male Sprague-Dawley rats (200–250 g, Harlan,
Horst, The Netherlands and 300–350 g, Charles River, Salzburg,
Germany in experiments assessing physiological function) and adult
male C57BL/6 mice (23–26 g, Charles River, Wilmington, MA, USA)
were used. They were housed in individually ventilated plastic cages in
light- and temperature-controlled rooms. Water and standard labora-
tory pellets were available ad libitum. After the placement of cisterna
magna cannulas, animals were single-housed for one day.
2.2. Drugs
Buprenorphine hydrochloride (Temgesic®, 0.3mg/mL, Indivior,
Slough, UK), carprofen (Rimadyl® vet, 50mg/mL, Pfizer, Espoo,
Finland), dexmedetomidine hydrochloride (Dexdomitor®, 0.5mg/mL,
Orion Pharma, Espoo, Finland), lidocaine hydrochloride (Lidocain®,
20 mg/mL, Orion Pharma), and morphine hydrochloride powder were
purchased from the University Pharmacy (Helsinki, Finland).
Oxycodone hydrochloride powder and naloxone hydrochloride powder
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Buprenorphine, carprofen, and dexmedetomidine were diluted in phy-
siological saline and administered subcutaneously in a volume of 2mL/
kg. Lidocaine was diluted to 5mg/mL and used for local infiltration
anesthesia. For intrathecal injections, morphine, naloxone, and oxyco-
done were diluted in sterile physiological saline.
2.3. Intracisternal cannulations and drug infusions
The cisterna magna cannulation procedure was performed as pre-
viously described with minor modifications [20]. In mice, intracisternal
cannulas were placed under ketamine-xylazine anesthesia. In rats, iso-
flurane 3% anesthesia was used. After verification of loss of response to
toe pinch, animals were placed in a stereotaxic frame with the neck
slightly flexed (30–40°). The atlanto-occipital membrane overlying the
cisterna magna was exposed and a 30G needle connected to a 4-cm long
PE10 tubing was carefully inserted into the intrathecal space. The ca-
theter was fixed to the dura with cyanoacrylate glue and dental cement.
Animals were monitored post-operatively and normothermia was
maintained with a heating pad. For post-operative analgesia, rats re-
ceived s.c. carprofen (5mg/kg) and buprenorphine (0.05mg/kg) at the
beginning of surgery.
On the morning of the next day after the cannulations, rats were
randomly allocated to either the awake group (saline) or the sedation
group (0.2mg/kg dexmedetomidine s.c.). Ten minutes after the injec-
tion, awake rats were gently guided into a restrainer on a heating pad.
Dexmedetomidine-sedated rats had lost the righting reflex by 10min
and were transferred to the heating pad and placed prone on it.
Oxycodone (100 nmol) and naloxone (100 nmol) or morphine
(100 nmol) and naloxone (100 nmol) were co-infused into the rat cis-
terna magna using a KD Scientific Legato® 130 pump (Holliston, MA,
USA) attached to a Hamilton Gastight 1700 microsyringe (Bonaduz,
Switzerland). The infusion rate of 1.6 μL/min was chosen based on
previous findings showing no effect on intracranial pressure with this
infusion rate (41). The total volume of 20 μL was infused over 12.5min,
with a total effective volume of 16 μL. After the infusion, animals in the
awake groups were kept awake by non-aversive sleep deprivation (in-
troduction of new object for exploration and gentle brushing), whereas
the dexmedetomidine-sedated rats were placed prone on a heating pad
in a quiet environment and kept normothermic. Depending on the ex-
periment, rats were killed by decapitation for collection of blood, brain
and spinal cord samples at 30, 60, or 120min after the beginning of the
infusion. The effects of dexmedetomidine on drug distribution in other
organs was not studied. All samples were collected and analyzed by
investigators blinded to the treatment groups.
To study amyloid-β antibody distribution, mice were either awake
or sedated with 0.018 or 0.2 mg/kg i.p. dexmedetomidine. After
10min, they were intracisternally infused 2% Alexa Fluor 488-con-
jugated anti-β-amyloid 1–16 antibody (clone 6E10, 1mg/mL;
BioLegend, catalog 803013) in artificial CSF over 5min using an infu-
sion rate of 2 μL/min (7). After a distribution period of 60min and
euthanasia by decapitation, brains were removed and drop-fixed in 4%
paraformaldehyde for 24 h.
2.4. EEG electrode implantation and EEG recordings
Rats were anesthetized with 2–3% isoflurane, and the head was
fixed in a stereotactic frame. Four holes (0.8mm) were drilled in the
skull bilaterally above the parietal and frontal cortex by using bregma,
lambda, and the midline as reference points. Great care was taken not
to damage the underlying dura. Two 0.8mm stainless steel screws
(NeuroTek, Wheat Ridge, CO, USA) were attached in the left hemi-
sphere holes to serve as anchors, and two low impedance stainless steel
screws (NeuroTek) were attached to the right hemisphere holes. After
implantation of all four bone screws, a thin layer of dental glue was
applied to cover the screws and allowed to dry, followed by application
of a layer of dental cement on top of the glue. The rats recovered in
controlled temperature and received s.c. carprofen (5mg/kg) post-
operatively and after 24 and 48 h.
For the EEG recordings, a shielded cable was connected to the re-
cording electrodes and to a preamplifier (Molecular Devices, San Jose,
CA, USA). Signals were digitized at a sampling rate of 500 Hz and
collected with Clampex software (Molecular Devices). The rat freely
moved around in a container while obtaining the baseline awake EEG.
After administration of dexmedetomidine or vehicle, EEG was recorded
continuously for the following 120min. For analysis, the recording was
divided into 5-min epochs and an artifact-free epoch from the awake
recording session was used as the baseline. EEG traces were analyzed
with Matlab (Mathworks, Natick, MA, USA). The EEG power was
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calculated for the delta (0.5–4 Hz), theta (4–8 Hz), and alpha fre-
quencies (8–12 Hz) by fast Fourier transform, and the percentage of
power in each frequency range was calculated from the total power of
the 0–50Hz spectrum.
2.5. Physiological measurements
Systolic and diastolic blood pressure and heart rate were assessed
with a non-invasive rat CODA Surgical Monitor (Kent Scientific,
Torrington, CT, USA). Respiratory rate was assessed by visual calcula-
tion over a 60-s period.
2.6. Small-molecule drug concentration measurements
Rats were decapitated and trunk blood was collected in K2-EDTA
tubes. Plasma was separated by centrifugation at 2000g for 10min at
+4 °C and stored at −80 °C. Brain (dorsal cortex, ventral cortex, dorsal
hippocampus, thalamus, hypothalamus) and spinal cord (lumbar en-
largement area) samples were carefully dissected, weighed, rinsed in
phosphate-buffered saline, snap-frozen in liquid nitrogen, and stored at
−80 °C before analysis. Tissue samples were homogenized and diluted
in 0.5–1mL of sterile water. The determination of morphine, naloxone,
and oxycodone was performed as described previously [21] with minor
modifications using SHIMADZU UHPLC Nexera X2 liquid chromato-
graphy system (SHIMADZU USA Manufacturing Inc. Canby, OR, USA)
coupled to an API 3000 tandem mass spectrometer (AB Sciex, Toronto,
Ontario, Canada) operating in a positive turbo ion spray mode. The
chromatographic separations were achieved on Atlantis HILIC Silica
column (3 μm particle size, 2.1× 100mm I.D.; Waters, Milford, MA,
USA) using a gradient elution of mobile phase consisting of acetonitrile
and 20mmol/L ammonium formate in 0.2% formic acid (v/v). An ali-
quot (10 μL) was injected at a flow rate of 200 μL/min to give a total
chromatographic run time of 22min. Deuterium-labelled standards
were used for morphine, oxycodone (Cerilliant, Round Rock, TX, USA),
and naloxone (Sigma-Aldrich). The target ion transitions monitored
were as follows: morphine m/z 286→ 152, naloxone m/z 328→253,
and oxycodone m/z 316→241. The limits of quantification (LOQ) were
3.5 pmol/mL morphine, 3.1 pmol/mL naloxone, and 0.79 pmol/mL
oxycodone. The calibration curves were linear over the concentration
range of LOQ–250 ng/mL, and day-to-day coefficients of variation were
below 15% within the relevant concentration range for all analytes.
None of the measured compounds interfered with the mass spectro-
metric assay.
2.7. Fluorescent antibody concentration analyses
Dorsal and ventral whole brain images were acquired on stereo-
microscope (MVX10, Olympus, Tokyo, Japan). Exposure times and
magnifications were kept the same for all groups. To allow qualitative
visual comparison of the effects of different doses of dexmedetomidine
on CSF tracer influx, a population-based average combining the images
from all groups was created for both the ventral and dorsal macroscopic
images. First, an initial average template was computed as the mean of
the nonaligned images. Then, all images were registered to this average
template, and a new mean of the aligned images was computed.
Registering and averaging were repeated with increasingly refined re-
gistration methods (three iterations of rigid registration, followed by
two affine registration iterations and lastly by three nonlinear regis-
tration iterations), resulting in the final population-based average
template. Last, all images were nonlinearly registered to the appro-
priate template to allow group comparisons. Image registration was
performed using Advanced Normalization Tools (ANTs) 2.1.0 [22] and
scripted with Python 3.6.
2.8. Statistical analysis
The data are presented as means ± SD. Two-tailed t-tests for re-
peated measurements with Holm-Sidak correction or analyses of var-
iance (ANOVA) followed by Holm-Sidak post hoc analysis were per-
formed. Statistical significance was ascribed at P < .05. The data were
analyzed using GraphPad Prism, version 7.0c for Mac OS X (GraphPad
Software, La Jolla, CA).
3. Results
3.1. Dexmedetomidine increases the brain delivery of an IgG-sized antibody
therapeutic
Using a method that has been previously validated for studying
glymphatic drug delivery [7], we first assessed whether dexmedeto-
midine could increase the brain delivery of an amyloid-ß antibody, an
example of an IgG-sized (~150 kDa) biological drug with no known
active transport at the BBB. Mice that had received cisterna magna
cannulas 24 h earlier received either dexmedetomidine or vehicle and
10min later a cisterna magna infusion of Alexa Fluor 488-conjugated
fluorescent amyloid-β antibody (Fig. 1A). After a distribution time of
60min, the brains were extracted, fixed, and analyzed for fluorescence
from both the dorsal and ventral sides (Fig. 1B–C). Because the mea-
surable penetration of IgG-sized drugs to deep brain structures is very
low, instead of using a standard coronal slice technique we used a
macroscopic technique that enables imaging of the entire ventral and
dorsal brain surfaces to a penetration depth of up to 1–2mm [7].
Glymphatic CSF influx assessed by macroscopic imaging highly corre-
lates with coronal slice analyses [16]. We found that whereas the low
dexmedetomidine (0.018mg/kg i.p.) dose did not have an effect com-
pared with vehicle, the high-dose dexmedetomidine treatment (0.2mg/
kg i.p.) approximately doubled the amyloid-ß antibody delivery to both
the dorsal and the ventral brain surfaces (Fig. 1D).
3.2. Effects of dexmedetomidine on physiological function
Having confirmed that dexmedetomidine increases the brain avail-
ability of an IgG-sized therapeutic, we continued the small-molecule
drug experiments in rats because of more tissue available for quanti-
tative mass spectrometry analyses in homogenized samples. We chose
the positive dose (0.2mg/kg) from the previous experiment and char-
acterized its effects on physiological parameters in rats after s.c. ad-
ministration (Fig. 2A). Dexmedetomidine caused a significant increase
in EEG delta power during the whole 120-min measurement period
(Fig. 2B), with a concomitant minor and non-significant decrease in the
alpha and theta powers. The blood pressure increased immediately
following dexmedetomidine administration and gradually decreased to
baseline levels thereafter (Fig. 2C), whereas heart rate and respiratory
rate were unaffected (Fig. 2D).
3.3. Systemic dexmedetomidine sedation enhances CNS delivery of
intrathecally administered oxycodone and naloxone
We then infused morphine together with the opioid antagonist na-
loxone to the cisterna magna of groups of awake (i.e. vehicle-treated) or
dexmedetomidine-sedated rats (Fig. 3A). We chose morphine as the first
intrathecally administered opioid, as it is frequently administered in
neuraxial anesthesia. Naloxone was co-infused with morphine to avoid
respiratory depression, opioid-induced sedation, and other potential
adverse effects of morphine. To identify the times of maximum con-
centration (Tmax) in the brain, we collected tissue and plasma samples
at 30, 60, and 120min after the start of the 12.5-min drug infusion.
Concentrations of both drugs were simultaneously determined using
high-performance mass spectrometry-tandem liquid chromatography.
Despite similar molar doses (100 nmol) of infused morphine and
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Fig. 1. Dexmedetomidine increases the distribution of intrathecally-infused fluorescent amyloid-β antibody to the brain ventral and dorsal surfaces as assessed by a
fluorescent macroscopic technique. (A) Mice received two doses of dexmedetomidine (Dex, 0.018mg/kg or 0.2mg/kg i.p.) or vehicle and 10min later an in-
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24 h. (B) Population-based average of amyloid-β antibody distribution at the dorsal and ventral brain surfaces. (C) Regions of interest (ROIS, shown in white) used for
the mean pixel intensity (MPI) measurements. (D) Dorsal and ventral region of interest MPI measurements for each brain. Measurements are divided into the vehicle,
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one-way ANOVA with Holm-Sidak post-test.
A
0–120 minDex 0.2 mg/kg s.c.
BL 20 40 60 80 100 120
0
20
40
60
80
Time (min)
%
 o
f E
EG
 p
ow
er
Delta (0.5–4 Hz)
Theta (4–8 Hz)
Alpha (8–12 Hz)
B
** ** ** ***** ***
20 40 60 80 100 120BL
80
100
120
140
160
180
200
Time (min)
Bl
oo
d 
pr
es
su
re
 (m
m
H
g)
MAP
BPsyst
BPdiast
C
***
***
***
***
***
***
**
**
**
* *
*
* *
20 40 60 80 100 120BL
50
100
150
300
350
400
Time (min)
HR
RR
Re
sp
ira
to
ry
 ra
te
(b
re
at
hs
/m
in
)
H
ea
rt
 ra
te
(b
ea
ts
/m
in
)
D
Fig. 2. Dexmedetomidine (0.2mg/kg, s.c.) induces sedation
with enhanced electroencephalogram (EEG) slow-wave delta
activity and transient hypertension, but is without effects on
respiratory or heart rate. (A) Simultaneous EEG, blood pres-
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medetomidine increased the systolic (BPsyst) and distolic
(BPdiast) blood pressure and mean arterial pressure (MAP) for
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naloxone, the morphine concentrations in the CNS were below the limit
of quantification, possibly due to very high drug efflux transport from
the CNS. Naloxone concentrations were quantifiable in all CNS regions.
The Tmax for naloxone in the awake rats occurred already at 30min
in most areas of interest (Fig. 3B–G), with a fast, subsequent con-
centration decline in the CNS. The dexmedetomidine-sedated rats
showed a distinctly different pharmacokinetic profile, with the na-
loxone Tmax occurring at 60min, and attaining markedly increased drug
exposure in the hippocampus, thalamus and hypothalamus compared
with the vehicle-treated rats. At 120min after infusions, naloxone
concentrations in the dexmedetomidine-sedated rats remained parti-
cularly high in the hippocampus and thalamus, clearly exceeding those
of the vehicle-treated rats. The plasma naloxone concentrations
(Fig. 3H) did not differ between vehicle and dexmedetomidine groups
at any observation time point, thus excluding peripheral factors such as
decreased systemic clearance.
Because we could not detect morphine concentrations in the CNS,
we studied another opioid agonist, oxycodone, that has active influx
transport to the brain (20). Oxycodone (100 nmol) was co-infused with
100 nmol naloxone, as above (Fig. 4A). We confined our focus to 60min
post infusion, the Tmax point found for naloxone in the previous ex-
periment. Compared with vehicle, dexmedetomidine treatment
increased concentrations of oxycodone by 24 to 96% in the spinal cord,
ventral cortex, dorsal cortex, thalamus, and hypothalamus, with highest
concentrations obtained in the dorsal cortex (Fig. 4B). As with findings
in the experiments with morphine, the naloxone concentrations were
markedly increased in the hippocampus, thalamus, and hypothalamus
of the sedated animals, with the highest concentrations in thalamus
(Fig. 4C). As dexmedetomidine did not influence the plasma con-
centrations of oxycodone and naloxone (Fig. 4D), we found increased
CNS region-to-plasma concentration ratios for both intrathecally ad-
ministered drugs (Fig. 4E–F).
3.4. Dexmedetomidine administered as an intrathecal adjuvant increases
CNS opioid exposure
In humans, dexmedetomidine is typically administered systemi-
cally, however, there are reports for off-label intrathecal use as an ad-
juvant to other anesthetics and analgesics [34]. We tested the hypoth-
esis that intrathecal dexmedetomidine could be used as an intrathecal
adjuvant with other small-molecule drugs to increase their access to the
CNS. In the experiment, cisterna magna cannulas were placed acutely
under brief isoflurane (3%) anesthesia. Isoflurane was maintained at
1.5% during the infusions and was discontinued afterwards. Rats first
30 12060
0
100
200
300
Time (min)
Co
nc
en
tr
at
io
n 
(p
m
ol
/g
)
Dorsal cortexD
30 12060
0
100
200
300
Time (min)
Co
nc
en
tr
at
io
n 
(p
m
ol
/g
)
Thalamus
*
***
F
30 12060
0
100
200
300
Time (min)
Co
nc
en
tr
at
io
n 
(p
m
ol
/g
)
Spinal cord
*
B
30 12060
0
100
200
300
Time (min)
Co
nc
en
tr
at
io
n 
(p
m
ol
/g
)
Ventral cortexC
30 12060
0
100
200
300
Time (min)
Co
nc
en
tr
at
io
n 
(p
m
ol
/g
)
Hypothalamus
*
G
30 12060
0
100
200
300
Time (min)
Co
nc
en
tr
at
io
n 
(p
m
ol
/g
)
Hippocampus
***
***
E
30 12060
0
50
100
Time (min)
Co
nc
en
tr
at
io
n 
(p
m
ol
/m
L)
Morphine 100 nmol and
naloxone 100 nmol i.t.
+ VEH s.c.
H
Morphine 100 nmol and 
naloxone 100 nmol i.t.
+ DEX 0.2 mg/kg s.c.
Naloxone plasma concentrations
Naloxone CNS concentrations
A Morphine 100 nmol and
Naloxone 100 nmol
i.t.
Vehicle or
Dex 0.2 mg/kg
s.c.
HPLC-MS analysis12.5 min
10 min 30–120 min
Fig. 3. Dexmedetomidine (Dex) increases the concentrations of intrathecally-infused naloxone in the brain and spinal cord at 60–120min after infusion. (A) Rats
received either vehicle or dexmedetomidine at −10min and an intracisternal infusion of morphine together with naloxone at 0min. To assess the time-concentration
profiles in the CNS, rats were killed at 30–120min after the beginning of the infusion, samples of brain regions, the spinal cord lumbar enlargement, and trunk blood
were collected. Morphine concentration measurements are not shown due to very low concentrations falling below the limit of quantification. (B–G)
Dexmedetomidine sedation increased the total naloxone concentration in the hippocampus, thalamus, and hypothalamus at 60min and in the spinal cord, hippo-
campus, and thalamus at 120min. Tmax, the time point of maximum naloxone concentration in dexmedetomidine-sedated rats was at 60min after infusion in all CNS
areas. (H) Dexmedetomidine sedation did not affect the plasma concentrations of intrathecally-infused naloxone. Means (± SD) are presented. ***P < .001,
*P < .05 (n=3–6); two-way ANOVA with Holm-Sidak post-test.
T.O. Lilius, et al. Journal of Controlled Release 304 (2019) 29–38
33
received an intracisternal infusion of either saline or dexmedetomidine
(8 μg in 16 μL) directly followed by oxycodone (100 nmol) and na-
loxone (100 nmol) (Fig. S1A). Samples were collected 60min after the
start of the infusion of oxycodone and naloxone. Intrathecal dexmede-
tomidine adjuvant increased both the oxycodone (Fig. S1B) and na-
loxone (Fig. S1C) concentrations in the three studied important loca-
tions for opioid analgesia; the spinal cord, thalamus, and dorsal cortex.
However, the magnitude of effect was slightly smaller than in the ex-
periments with systemic dexmedetomidine. The greatest increase in
oxycodone concentrations by dexmedetomidine was 41% in the spinal
cord. The plasma concentrations of oxycodone or naloxone did not
differ between groups (Fig. S1D). The CNS-to-plasma concentration
ratio of oxycodone (Fig. S1E) was significantly increased in the spinal
cord and thalamus by dexmedetomidine, however, for naloxone there
was no significant change (Fig. S1F).
Finally, to rule out a potential system-level pharmacokinetic inter-
action between dexmedetomidine, oxycodone, and naloxone, we ad-
ministered subcutaneous dexmedetomidine (0.2 mg/kg) or vehicle fol-
lowed by oxycodone and naloxone (1mg/kg each, s.c.) (Fig. S2A).
Dexmedetomidine did not significantly affect plasma oxycodone or
naloxone concentrations at 30 or 60min after administration or CNS
concentration at 60min after administration (Fig. S2B–E).
Consequently, the CNS region-to-plasma concentration ratios of sys-
temically administered oxycodone and naloxone were not changed by
dexmedetomidine (Fig. S2F–G).
4. Discussion
We found that both systemic and intrathecal dexmedetomidine
substantially increased the delivery of two intrathecally administered
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Fig. 4. Dexmedetomidine (Dex) enhances the delivery of intrathecally-administered oxycodone and naloxone to the brain and spinal cord. (A) Rats received either
vehicle or dexmedetomidine at −10min and an intracisternal infusion of oxycodone and naloxone at 0min. Rats were killed at 60min, based on results of previous
experiment showing the maximum naloxone concentrations (Tmax) for at 60min. (B) Dexmedetomidine increased the concentrations of oxycodone at several CNS
areas relevant to antinociception, including the spinal cord lumbar enlargement, cortex and thalamus. The greatest increase (96%) was observed in the hypotha-
lamus. (C) In agreement with the previous experiment, dexmedetomidine increased also the naloxone concentrations in the hippocampus, thalamus and hypotha-
lamus at 60min. (D) Corresponding plasma concentrations of oxycodone and naloxone did not reveal any differences between groups. (E–F) The CNS region-to-
plasma concentration ratios for oxycodone and naloxone increased in the treatment group, indicating increased brain availability. Means (± SD) are shown
(n=6–7). **P < .01, *P < .05; t-test with Holm-Sidak correction for multiple comparisons.
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small-molecule drugs, oxycodone and naloxone, to the brain and spinal
cord. Systemic dexmedetomidine increased the CNS oxycodone con-
centration in several CNS areas, ranging from a 24% increase in the
hippocampus to a 96% increase in the hypothalamus region. The in-
creases in naloxone concentrations were of similar magnitude.
Importantly, the CNS-to-plasma concentration ratios of intrathecally
administered oxycodone and naloxone were both increased by dex-
medetomidine, predicting greater exposure to the drugs. In systemic co-
administration, neither the mean CNS and plasma concentrations nor
the corresponding CNS-to-plasma concentration ratios for oxycodone
and naloxone were affected, ruling out any significant systemic phar-
macokinetic interaction or altered competition for transport at the BBB.
In addition to the small-molecule drugs, dexmedetomidine also in-
creased the brain delivery of an intrathecally administered IgG-sized
therapeutic as assessed by standard fluorescent methods. We propose
that the glymphatic drug delivery pathway evidently activated by
dexmedetomidine can be utilized to enhance CNS delivery of ther-
apeutics upon intrathecal administration.
The study shows that pharmacologic activation of the glymphatic
pathway can enhance the CNS distribution of drugs of low molecular
weight (~300 Da). After intrathecal infusion, we detected significant
oxycodone concentrations in brain areas important for its analgesic
actions, such as the spinal cord, thalamus, and cortex. In the first de-
monstration of the glymphatic system [6], the lowest molecular weight
tracer Alexa 594 hydrazide (759 Da), with a molecular size approxi-
mately 2.5 times greater than that of oxycodone, rapidly disseminated
throughout the brain after infusion into the cisterna magna [6]. That
finding is in line with our present results, showing rather uniform dis-
tribution of oxycodone and naloxone across the brain interstitium.
While in the awake rats the naloxone Cmax was reached already at
the 30-min time point in several brain regions, treatment with dex-
medetomidine increased both the Cmax and Tmax. This finding is in
agreement with a rat magnetic resonance imaging (MRI) study, where
dexmedetomidine supplementation also delayed the whole-brain Tmax
for the small-molecule MRI contrast agent gadopentetic acid (938 Da)
[23]. We hypothesize that when the animals are awake, CSF is rapidly
effluxed from the CNS via CSF exit routes such as nasal lymphatic
vessels and very little enters the perivascular spaces and glymphatic
pathway [7]. Dexmedetomidine, in contrast, may allow more CSF to
reach the perivascular spaces of large arteries and carry dissolved drugs
to the parenchyma.
This is the first study to test the effects of dexmedetomidine
monotherapy on intrathecal delivery of clinically relevant drugs to the
CNS. Stimulation of α2-adrenergic autoreceptors by dexmedetomidine
decreases the activity of locus coeruleus and norepinephrine release
throughout the CNS [24,25], observed as sedation and increased slow-
wave EEG oscillations [19], as in our study. In previous studies, keta-
mine-xylazine anesthesia that dramatically increases slow-wave oscil-
lations enhanced the access of intracisternally-infused fluorescent CSF
tracers to pial perivascular spaces [7] and brain parenchyma [15]. A
recent study comparing six different anesthetic regimens highlighted a
strong correlation between EEG delta power and CSF influx [16], and
supplementing low-concentration isoflurane anesthesia with dexmede-
tomidine increased glymphatic transport compared with high-con-
centration isoflurane anesthesia alone [23]. The increase in glymphatic
flow induced by NREM sleep-like states has been attributed to a de-
crease in astrocytic volume in the CNS parenchyma and a concomitant
decrease in extracellular flow resistance due to higher interstitial vo-
lume [15]. Recently it was shown that cerebral arterial wall pulsatility
induced by the cardiac cycle is the main driver of fluid in perivascular
spaces of pial arteries [26]. Since dexmedetomidine may have cerebral
vascular effects, further mechanistic studies are needed to assess the
effects of dexmedetomidine on cerebral arterial wall pulsatility, peri-
arterial size, and fluid flow. Taken together, there is increasing evi-
dence that α2-agonists could be useful in enhancing glymphatic flow
and promoting drug delivery to the CNS.
In our study, morphine concentrations in the CNS were below the
limit of quantification by our method, although naloxone and oxyco-
done could be reliably quantified. Morphine is a substrate of the drug
efflux transporter P-glycoprotein [27,28] that is widely expressed not
only at the BBB endothelium [29] but also at the arachnoid villus
membranes [30], making morphine prone to efflux transport at several
stages and possibly leading to very low CNS concentrations. Oxycodone
shares many physicochemical properties with morphine and other
water-soluble strong opioid analgesics [31]. However, in contrast to
morphine, oxycodone has facilitated influx transport to the CNS at the
BBB [32], which evidently predominates over efflux processes in our
cisterna magna infusion model, whereas efflux must be the major factor
in the case of morphine. Naloxone is a relatively lipid-soluble opioid
antagonist with no known active transport at the BBB. In our study,
despite a similar absolute dose of oxycodone and naloxone infused, we
generally found higher naloxone than oxycodone concentrations in the
CNS (Fig. 4), supposedly due to higher lipophilicity and increased in-
tracellular penetration. The effect of dexmedetomidine on drug CNS
delivery was slightly more pronounced in the case of oxycodone,
probably because it is more prone to glymphatic fluxes due to its hy-
drophilicity. Further studies with a wider range of tracer molecules are
needed to characterize the effects of CNS drug transporters and drug
physicochemical properties on glymphatic CSF-ISF drug delivery.
The concentration of oxycodone in the spinal cord, the main target
of opioids, was increased by 70% and 41% after systemic and in-
trathecal dexmedetomidine, respectively (Fig. 4B and S1B). In clinical
anesthesia practice, intravenous and intrathecal α2-agonists such as
dexmedetomidine and clonidine have shown synergistic effects when
combined with intrathecal opioids [33] and sodium channel blocker
anesthetics such as bupivacaine and ropivacaine [34–39], leading to
enhanced or prolonged analgesia. These beneficial effects have been
explained by supposedly additive pharmacodynamic effects at the re-
ceptor level. Based on our findings, it is compelling to hypothesize that
the beneficial effects of adjunct α2-agonists may be in part due to a
pharmacokinetic mechanism whereby dexmedetomidine leads to en-
hanced CSF-ISF fluid exchange and thus increased exposure. Indeed,
our study raises a question whether other classes of intrathecal ther-
apeutics such as antineoplastic compounds could be infused under
dexmedetomidine sedation to enhance their glymphatic delivery to the
CNS. Our proposal for a mechanism of action for dexmedetomidine in
the enhanced delivery of intrathecally-administered small-molecule
opioids is presented schematically in Fig. 5.
Dexmedetomidine is a relatively safe sedative agent that has been
approved also for procedural sedation [17,18]. The main adverse ef-
fects are related to hemodynamic changes; at low plasma concentra-
tions it reduces sympathetic outflow, often leading to hypotension [17].
However, higher concentrations may lead to transient hypertension due
to the stimulation of vasopressor α2B-adrenoreceptors [40], as seen in
the present study and also in humans [41,42]. In our study, the 0.2mg/
kg dose was selected to produce hypnosis, immobility and loss of
righting reflex for 2 h. The monitored plasma concentration was
8.8 ± 0.8 ng/mL (n=4) at 60min after administration. In humans,
the therapeutic plasma concentration is 0.4–1.2 ng/mL for sedation and
approximately 3.2 ng/mL for inducing loss of consciousness [42],
however, concentrations as high as 14.7 ng/mL have been observed
[43]. The concentrations used in humans for inducing loss of con-
sciousness may be high enough to show enhancement of glymphatic
flow and drug delivery.
An aspect that warrants further investigation concerns the phar-
macokinetics after lumbar intrathecal administration, as opposed to the
cisterna magna. The process may be slower in humans due to longer
diffusion and influx distances. Indeed, a clinical study that assessed the
kinetics of the magnetic contrast agent gadobutrol (605 Da) infused to
the lumbar intrathecal space showed that the peak contrast enhance-
ment in most of the studied deep cerebral areas occurred 24 h after
tracer injection [44]. Enhancing drug exposure with procedural
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dexmedetomidine sedation could have the greatest potential in deli-
vering drugs that target the spinal cord near the site of infusion, such as
the oligonucleotide nusinersen [3] used in the treatment of spinal
muscular atrophy. The time needed to reach the target in spinal cord
would likely be faster than in brain. Another non-pharmacological
strategy to improve the glymphatic delivery of intrathecal therapeutics
would be to administer them in the evening, i.e. before sleep. Due to
daily clinical routines, most intrathecal infusions are administered
during regular working hours, when the glymphatic pathway is disen-
gaged.
5. Conclusions
Dexmedetomidine monotherapy increases the CNS delivery of in-
trathecally administered drugs in the rat brain and spinal cord by en-
hancing glymphatic transport. This phenomenon could potentially be
utilized to enhance the delivery and efficacy of intrathecal therapeutics
used in the treatment of CNS diseases. As sedation is frequently in-
dicated for intrathecal drug delivery, clinical trials should be designed
to study the effects of dexmedetomidine on drug delivery and response.
Future studies with drugs with different physicochemical properties are
needed to maximize the potential of the glymphatic system in drug
delivery and to improve the safety and efficacy of intrathecally ad-
ministered therapeutics.
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